Details checkedStatus confirmedHistorical/discontinuedCheckedcompany

AM-111 by Auris Medical and Altamira

Also known as: AM-111, Sonsuvi, brimapitide

Altamira Therapeutics

Primary source

Company

Altamira Therapeutics

Program Type

Therapeutic

Modality

Biologic

Stage

Phase 3

Status

Discontinued

Target Gene

—

Route / Mode

Intratympanic injection

Confidence

95%

Status Confidence

Status confirmed

Evidence Strength

Needs more support

Last Reviewed

2026-05-31

Geography

Europe, Asia, United States

Population

adult, sudden, profound

Trial IDs

Mechanism

Intratympanic cell-penetrating peptide JNK inhibitor designed to protect cochlear cells in acute inner-ear hearing loss.

Indications

Hearing Loss Sensorineural Hearing Loss Sudden Sensorineural Hearing Loss

Notes

Late-stage, field-shaping SSNHL program that failed overall in Phase 3 despite post-hoc signal discussions in profound acute hearing loss.

Evidence & Sources

3 structured sources

company

Supports: canonicalName, aliases, stage, status, indications, notes

IDs: AM-111, Sonsuvi

Open

company

Supports: company, allCompanies, route, notes

IDs: AM-111, Sonsuvi

Open

publication

Supports: notes

IDs: HEALOS

Open

Key Events

2017-11-28

Auris reported top-line Phase 3 HEALOS results for AM-111

Clinical Trials (3)

NCT02809118 NCT02561091 NCT00802425

Related Programs

Otarmeni by Regeneron

Company: Regeneron Pharmaceuticals · Gene Therapy · Approved

PEDMARK by Fennec Pharmaceuticals

Company: Fennec Pharmaceuticals · Small Molecule · Marketed

AK-OTOF by Eli Lilly and Akouos

Company: Eli Lilly and Company · Gene Therapy · Phase 2

SENS-401 (Arazasetron) by Sensorion

Company: Sensorion · Small Molecule · Phase 2

SENS-501 by Sensorion

Company: Sensorion · Gene Therapy · Phase 1/2

Rincell-1 by Rinri Therapeutics

Company: Rinri Therapeutics · Cell Therapy · Phase 1/2